Scarica l'app Stockscreener
1.20
1.69%
0.02
Dopo l'orario di chiusura:
1.20
Precedente Chiudi:
$1.18
Aprire:
$1.19
Volume 24 ore:
4.81M
Relative Volume:
1.51
Capitalizzazione di mercato:
$319.35M
Reddito:
$95,000
Utile/perdita netta:
$-327.27M
Rapporto P/E:
-0.566
EPS:
-2.12
Flusso di cassa netto:
$-239.25M
1 W Prestazione:
-3.23%
1M Prestazione:
-5.51%
6M Prestazione:
-45.45%
1 anno Prestazione:
-44.44%
Intervallo 1D:
$1.18
$1.29
Intervallo di 1 settimana:
$1.11
$1.29
Portata 52W:
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Nome
Allogene Therapeutics Inc
Settore
Industria
Telefono
(650) 457-2700
Indirizzo
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Confronta ALLO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.20 | 319.35M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-14 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | Ripresa | Oppenheimer | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-01-05 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-01-05 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | Iniziato | Citigroup | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-06 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-08-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-03 | Iniziato | Robert W. Baird | Neutral |
| 2022-02-28 | Reiterato | B. Riley Securities | Buy |
| 2021-10-20 | Iniziato | Cowen | Outperform |
| 2021-10-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-10-08 | Downgrade | Stifel | Buy → Hold |
| 2021-09-23 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | Ripresa | Jefferies | Buy |
| 2021-05-20 | Aggiornamento | Truist | Hold → Buy |
| 2021-05-14 | Iniziato | B. Riley Securities | Buy |
| 2021-01-26 | Aggiornamento | Stifel | Hold → Buy |
| 2020-12-10 | Ripresa | H.C. Wainwright | Buy |
| 2020-11-24 | Iniziato | BofA Securities | Buy |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-06-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-19 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2020-05-15 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-05-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-14 | Downgrade | SunTrust | Buy → Hold |
| 2020-04-13 | Iniziato | SunTrust | Buy |
| 2020-03-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-24 | Iniziato | Berenberg | Hold |
| 2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-11-04 | Iniziato | Canaccord Genuity | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-06-05 | Iniziato | ROTH Capital | Neutral |
| 2019-05-31 | Iniziato | Guggenheim | Neutral |
| 2019-05-23 | Iniziato | Stifel | Hold |
| 2019-03-29 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Allogene Therapeutics Inc Borsa (ALLO) Ultime notizie
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Allogene’s SWOT analysis: stock outlook amid clinical delays, promising data By Investing.com - Investing.com India
Allogene’s SWOT analysis: stock outlook amid clinical delays, promising data - Investing.com
Allogene's SWOT analysis: stock outlook amid clinical delays, promising data - Investing.com
Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN
Insider Sell: Deborah Messemer Sells 36,885 Shares of Allogene T - GuruFocus
Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report? - Yahoo Finance
Shareholders May Find It Hard To Justify Increasing Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation For Now - simplywall.st
Allogene Therapeutics at Jefferies Conference: Delays and Optimism By Investing.com - Investing.com Canada
All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy - Yahoo Finance
Allogene Therapeutic's ALLO-316 Shows Durable Responses in Advanced Renal Cell Carcinoma - CRISPR Medicine News
Allogene Therapeutics Presents Promising Phase 1 Data for ALLO-316 in Renal Cell Carcinoma - MSN
Citi maintains buy rating on Allogene stock following ASCO data - Investing.com Australia
Citi maintains buy rating on Allogene stock following ASCO data By Investing.com - Investing.com India
Allogene Therapeutics (ALLO) Showcases Promising Data from Phase 1 TRAVERSE Study | ALLO Stock News - GuruFocus
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting - GuruFocus
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO | ALLO Stock News - GuruFocus
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO - The Manila Times
Allogene Therapeutics Highlights Promising Phase 1 Results of ALLO-316 in Advanced Renal Cell Carcinoma at ASCO 2025 - Nasdaq
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses With Allo-316 In Heavily Pretreated Advanced Renal Cell Carcinoma At ASCO - MarketScreener
Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment - Seeking Alpha
Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade) - Seeking Alpha
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Raises Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Allogene at TD Cowen’s Summit: Strategic Insights on CAR T-Cell Therapy - Investing.com Canada
Allogene Therapeutics’s SWOT analysis: CAR-T pioneer’s stock faces pivotal year - Investing.com
Analysts Are Bullish on These Healthcare Stocks: Cidara Therapeutics (CDTX), Merus (MRUS) - The Globe and Mail
Allogene Therapeutics Announces Participation in Upcoming Invest - GuruFocus
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - The Manila Times
Allogene Therapeutics Lines Up Strategic Presentations at Goldman Sachs, Jefferies Healthcare Events - Stock Titan
Allogene shares update on CAR T-cell therapies at ASCO meeting - Investing.com Australia
Allogene Therapeutics Announces ASCO 2025 Abstract Publication F - GuruFocus
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel - The Manila Times
Allogene shares update on CAR T-cell therapies at ASCO meeting By Investing.com - Investing.com South Africa
Allogene Therapeutics Announces Upcoming Presentations at ASCO 2025 Featuring ALLO-316 and ALPHA3 Trial Data - Nasdaq
Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M - simplywall.st
Allogene extends cash runway into 2027 while prioritizing ALPHA3 and clinical momentum - MSN
Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com
Citigroup Issues Pessimistic Forecast for Allogene Therapeutics (NASDAQ:ALLO) Stock Price - Defense World
Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff - BioPharma Dive
Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays - GuruFocus
ALLO: Citigroup Lowers Price Target But Maintains Buy Rating | A - GuruFocus
Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Allogene Therapeutics Inc Azioni (ALLO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):